Gemina Laboratories Past Earnings Performance
Past criteria checks 0/6
Gemina Laboratories's earnings have been declining at an average annual rate of -35.3%, while the Biotechs industry saw earnings growing at 13.8% annually. Revenues have been declining at an average rate of 77.1% per year.
Key information
-35.3%
Earnings growth rate
-16.8%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | -77.1% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Oct 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Gemina Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Oct 23 | 0 | -6 | 3 | 3 |
| 31 Jul 23 | 0 | -6 | 3 | 4 |
| 30 Apr 23 | 0 | -7 | 2 | 4 |
| 31 Jan 23 | 0 | -6 | 2 | 4 |
| 31 Oct 22 | 0 | -5 | 2 | 3 |
| 31 Jul 22 | 0 | -6 | 2 | 4 |
| 30 Apr 22 | 0 | -4 | 2 | 3 |
| 31 Jan 22 | 0 | -5 | 2 | 3 |
| 31 Oct 21 | 0 | -4 | 2 | 2 |
Quality Earnings: GLAB is currently unprofitable.
Growing Profit Margin: GLAB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GLAB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GLAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: GLAB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.